Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 3,982,000 | 4,711,000 | 4,480,000 | 4,176,000 | 3,891,000 |
| Cost of Goods | 2,011,000 | 2,056,000 | 2,176,000 | 2,074,000 | 2,014,000 |
| Gross Profit | 1,972,000 | 2,655,000 | 2,304,000 | 2,102,000 | 1,877,000 |
| Operating Expenses | 1,319,000 | 2,355,000 | 1,422,000 | 1,647,000 | 1,356,000 |
| Operating Income | 652,000 | 300,000 | 882,000 | 455,000 | 521,000 |
| Other Income | -216,000 | -208,000 | -234,000 | -251,000 | -227,000 |
| Pre-tax Income | 436,000 | 92,000 | 648,000 | 204,000 | 294,000 |
| Income Tax | 67,000 | -390,000 | 214,000 | -78,000 | 74,000 |
| Net Income Continuous | 369,000 | 482,000 | 434,000 | 282,000 | 220,000 |
| Minority Interests | N/A | N/A | 1,000 | N/A | 6,000 |
| Net Income | $369,000 | $481,000 | $433,000 | $283,000 | $214,000 |
| EPS Basic Total Ops | 0.32 | 0.41 | 0.38 | 0.25 | 0.19 |
| EPS Basic Continuous Ops | 0.32 | 0.42 | 0.38 | 0.25 | 0.19 |
| EPS Diluted Total Ops | 0.31 | 0.42 | 0.37 | 0.24 | 0.18 |
| EPS Diluted Continuous Ops | 0.31 | 0.41 | 0.37 | 0.24 | 0.19 |
| EPS Diluted Before Non-Recurring Items | 0.50 | 0.93 | 0.75 | 0.64 | 0.49 |
| EBITDA(a) | $891,000 | $560,000 | $1,130,000 | $705,000 | $765,000 |